The Relationship Between Efficacy Of PEG-interferon And HLA-DRB1 Alleles In The Patients With Chronic Hepatitis B

Objective To study the relationship between efficacy of PEG-interferona-2a for forty-eight weeks and some HLA alleles (HLA-DRB1) in the patients with chronic viral hepatitis B from Qingdao of the Han nationality, it has very important theoretic practical meaning to guide clinical treatment of antivirus of patients with chronic viral hepatitis B, and to Screen indicated patients, and to elevate efficacy of antivirus. It provides immuno-genetic knowledge for the prevention and cure of hepatitis B virus infection.Methods Forty patients with chronic viral hepatitis B in a Qingdao population of the Han nationality were subjected to a standard course of treatment with PEG-interferona-2a for 48 weeks. HLA-DRB 1~*04,~*07 were detected by using the polymerase chain reaction-sequence specific primer(PCR-SSP) technique. The data were analysed by SC2000 software.Results After forty patients with chronic viral hepatitis B were subjected to a course of treatment with PEG-interferona-2a for 48 weeks, there were nineteen patients in the complete-responders(47.5%), and ten patients in the partial-responders(25%), and eleven patients in non-responders(27.5%). The patients of HLA-DRB1~*04 in eleven non-responders were four, and in twenty-nine partial- or complete-responders was one. The frequency of HLA-DRB 1~*04 in non-responders was higher than that in the partial-or complete-responders (P＜0.05, OR=16.0). The patients of HLA-DRB1~*07 in eleven non-responders were seven, and in twenty-nine partial- or complete-responders were six. The frequency of HLA-DRB 1~*07 in non-responders was higher than that in the partial- or complete-responders (P＜0.05, OR=6.7).Conclusions In a Qingdao population of the Han nationality, no response of PEG-interferona-2a therapy in the patients with chronic viral hepatitis B was correlated positively with HLA-DRB 1~*04~*,07. It establishes theoretic foundation for the prediction of efficacy of PEG-interferon, and provides theoretic knowledge for the rational therapy of patients with chronic viral hepatitis B.